Literature DB >> 20307709

Hematopoietic stem cell transplantation for leukemia.

Alan S Wayne1, Kristin Baird, R Maarten Egeler.   

Abstract

Leukemia represents the most common pediatric malignancy, accounting for approximately 30% of all cancers in children less than 20 years of age. Most children diagnosed with leukemia are cured without hematopoietic stem cell transplantation (HSCT), but for some high-risk subgroups, allogeneic HSCT plays an important role in their therapeutic approach. The characteristics of these high-risk subgroups and the role of HSCT in childhood leukemias are discussed. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2010        PMID： 20307709      PMCID： PMC2913522          DOI： 10.1016/j.pcl.2009.11.005

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN： 0031-3955            Impact factor:   3.278


  167 in total

Review 1.  Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements.

Authors:  C-H Pui; J M Chessells; B Camitta; A Baruchel; A Biondi; J M Boyett; A Carroll; O B Eden; W E Evans; H Gadner; J Harbott; D O Harms; C J Harrison; P L Harrison; N Heerema; G Janka-Schaub; W Kamps; G Masera; J Pullen; S C Raimondi; S Richards; H Riehm; S Sallan; H Sather; J Shuster; L B Silverman; M G Valsecchi; E Vilmer; Y Zhou; P S Gaynon; M Schrappe
Journal:  Leukemia       Date:  2003-04       Impact factor: 11.528

2.  Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a pediatric oncology group study .

Authors:  A K Ritchey; B H Pollock; S J Lauer; Y Andejeski; J Barredo; G R Buchanan
Journal:  J Clin Oncol       Date:  1999-12       Impact factor: 44.544

3.  Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL).

Authors:  B Wassmann; H Pfeifer; U Scheuring; S A Klein; N Gökbuget; A Binckebanck; H Martin; H Gschaidmeier; D Hoelzer; O G Ottmann
Journal:  Leukemia       Date:  2002-12       Impact factor: 11.528

Review 4.  A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases.

Authors:  H Hasle; C M Niemeyer; J M Chessells; I Baumann; J M Bennett; G Kerndrup; D R Head
Journal:  Leukemia       Date:  2003-02       Impact factor: 11.528

5.  Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience.

Authors:  John M Goldberg; Lewis B Silverman; Donna E Levy; Virginia Kimball Dalton; Richard D Gelber; Leslie Lehmann; Harvey J Cohen; Stephen E Sallan; Barbara L Asselin
Journal:  J Clin Oncol       Date:  2003-10-01       Impact factor: 44.544

6.  Impact of marrow unrelated donor search duration on outcome of children with acute lymphoblastic leukemia in second remission.

Authors:  G Dini; M Grazia Valsecchi; C Micalizzi; A Busca; A Balduzzi; W Arcese; S Cesaro; A Prete; M Rabusin; E Mazzolari; P Di Bartolomeo; N Sacchi; A Pession; G Giorgiani; E Lanino; T Lamparelli; C Favre; A Bosi; C Manzitti; S Galimberti; F Locatelli
Journal:  Bone Marrow Transplant       Date:  2003-08       Impact factor: 5.483

7.  Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891.

Authors:  Alan S Gamis; William G Woods; Todd A Alonzo; Allen Buxton; Beverly Lange; Dorothy R Barnard; Stuart Gold; Franklin O Smith
Journal:  J Clin Oncol       Date:  2003-07-28       Impact factor: 44.544

8.  Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia.

Authors:  Anthony V Moorman; Sue M Richards; Mary Martineau; Kan Luk Cheung; Hazel M Robinson; G Reza Jalali; Zoe J Broadfield; Rachel L Harris; Kerry E Taylor; Brenda E S Gibson; Ian M Hann; Frank G H Hill; Sally E Kinsey; Tim O B Eden; Christopher D Mitchell; Christine J Harrison
Journal:  Blood       Date:  2003-06-26       Impact factor: 22.113

Review 9.  Management decisions in chronic myeloid leukemia.

Authors:  John M Goldman; David Marin
Journal:  Semin Hematol       Date:  2003-01       Impact factor: 3.851

10.  Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study.

Authors:  N Bunin; R Aplenc; N Kamani; K Shaw; A Cnaan; S Simms
Journal:  Bone Marrow Transplant       Date:  2003-09       Impact factor: 5.483
View more
  9 in total

1.  Effects of dendritic cell-activated and cytokine-induced killer cell therapy on 22 children with acute myeloid leukemia after chemotherapy.

Authors:  Yan Bai; Jin-E Zheng; Nan Wang; He-Hua Cai; Li-Na Zhai; Yao-Hui Wu; Fang Wang; Run-Ming Jin; Dong-Feng Zhou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-10-22

2.  High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia.

Authors:  Wing Leung; Dario Campana; Jie Yang; Deqing Pei; Elaine Coustan-Smith; Kwan Gan; Jeffrey E Rubnitz; John T Sandlund; Raul C Ribeiro; Ashok Srinivasan; Christine Hartford; Brandon M Triplett; Mari Dallas; Asha Pillai; Rupert Handgretinger; Joseph H Laver; Ching-Hon Pui
Journal:  Blood       Date:  2011-05-25       Impact factor: 22.113

3.  Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.

Authors:  Wing Leung; Ching-Hon Pui; Elaine Coustan-Smith; Jie Yang; Deqing Pei; Kwan Gan; Ashok Srinivasan; Christine Hartford; Brandon M Triplett; Mari Dallas; Asha Pillai; David Shook; Jeffrey E Rubnitz; John T Sandlund; Sima Jeha; Hiroto Inaba; Raul C Ribeiro; Rupert Handgretinger; Joseph H Laver; Dario Campana
Journal:  Blood       Date:  2012-04-19       Impact factor: 22.113

4.  Hematopoietic Stem Cell Transplantation for Childhood Acute Lymphoblastic Leukemia and the Role of MRD: A Single Centre Experience from India.

Authors:  Divya Subburaj; Lakshman Vaidyanathan; Ramya Uppuluri; Dhaarani Jayaraman; Revathi Raj
Journal:  Indian J Hematol Blood Transfus       Date:  2017-05-20       Impact factor: 0.900

5.  Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies.

Authors:  Elad Jacoby; Allen Chen; David M Loeb; Christopher J Gamper; Elias Zambidis; Nicolas J Llosa; Jeffrey Huo; Kenneth R Cooke; Rick Jones; Ephraim Fuchs; Leo Luznik; Heather J Symons
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-04       Impact factor: 5.742

Review 6.  Hematopoietic stem cell stretches and moves in its bone marrow niche.

Authors:  Walison N Silva; Alinne C Costa; Caroline C Picoli; Beatriz G S Rocha; Gabryella S P Santos; Pedro A C Costa; Parviz Azimnasab-Sorkhabi; Maryam Soltani-Asl; Rodrigo A da Silva; Jaime Henrique Amorim; Rodrigo R Resende; Akiva Mintz; Alexander Birbrair
Journal:  Crit Rev Oncol Hematol       Date:  2021-05-26       Impact factor: 6.625

7.  Hematopoietic stem cell transplantation activity and trends at a pediatric transplantation center in Turkey during 1998-2008.

Authors:  Volkan Hazar; Gülsün Karasu; Vedat Uygun; Mediha Akcan; Alphan Küpesiz; Akif Yeşilipek
Journal:  Turk J Haematol       Date:  2012-06-15       Impact factor: 1.831

8.  Backtracked analysis of preleukemic fusion genes and DNA repair foci in umbilical cord blood of children with acute leukemia.

Authors:  Milan Škorvaga; Matúš Durdík; Pavol Košík; Eva Marková; Marek Holop; Miroslav Kubeš; Judita Puškáčová; Alexandra Kolenová; Igor Belyaev
Journal:  Oncotarget       Date:  2018-04-10

9.  A New Predictive Technology for Perinatal Stem Cell Isolation Suited for Cell Therapy Approaches.

Authors:  Silvia Zia; Giulia Martini; Valeria Pizzuti; Alessia Maggio; Giuliana Simonazzi; Pierluigi Reschiglian; Laura Bonsi; Francesco Alviano; Barbara Roda; Andrea Zattoni
Journal:  Micromachines (Basel)       Date:  2021-06-30       Impact factor: 2.891
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.